secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-202446
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio prices $150M underwritten offering of 51.7M shares at $2.90; net proceeds ~$141M
--------------------------------------------------------------------------------

- 51,725,000 shares offered at $2.90; net proceeds ~$141M after underwriting discounts and expenses.
- Offering includes participation from Bain Capital Life Sciences, Adage Capital, Cormorant Asset Management, and Eli Lilly.
- Preliminary cash & equivalents as of March 31, 2026: $117M.
- Net proceeds to fund expanded clinical development of rese-cel (myositis registrational study and additional indications) and manufacturing for commercial readiness.
- Company expects cash runway into mid-2027 based on current operating plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/d145767d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-202446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer